Previous close | 44.22 |
Open | 44.93 |
Bid | 43.65 x 200 |
Ask | 44.10 x 200 |
Day's range | 43.81 - 45.26 |
52-week range | 15.76 - 49.58 |
Volume | |
Avg. volume | 807,070 |
Market cap | 3.424B |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Jeff Knight, the Chief Operating Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 32,359 shares of the company on March 22, 2024, according to a recent SEC filing.
Chief Medical and Development Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 15,089 shares of the company on March 20, 2024, according to a recent SEC filing.
Director Matthew Fust has sold 60,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on March 20, 2024, according to a recent SEC Filing.